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The aim of this study was to evaluate and compare the effects of Na Valproate 
and Phenobarbital on changes in the weight of epileptic patients following 
treatment for their condition using the drugs mentioned.
Materials and methods
Sixty epileptics were assigned into two groups of 30 patients each, the case 
and controls. The diagnosis was made on the basis of the International 
League Against Epilepsy (ILAE) characteristics. BMI was defined. In the case 
group, the patients received 20mg/kg/day of Na Valproate, while the 30 
controls received 5mg/kg/day of Phenobarbital for 6 months. Using the Mc 
Nemar and Chi-2 tests, BMI changes were compared after 6 months between 
the groups. Fisher’s exact test was used to evaluate the role of age, sex, and 
primary weight on the weight increase due to Na Valproate usage.
Results
There were no specific changes in age, sex, primary BMI and fatness between 
the 2 groups; in the case group, 20 patients(66.7%) and in the controls 4(13.3%) 
gained weight (P<0.001). There were higher chances of weight gain in children 
who were older and fatter at the beginning of the study (P<0.2).
Conclusion
The results indicate that epileptic children, aged over 10 years, and those 
who are overweight have more chances of gaining weight or becoming fatter, 
following treatment with Na Valproate. Further studies investigating the issue 
are warranted.
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Introduction
A major problem encountered in most societies by children is fatness (1).
In children, the prevalence ranges between 16 to 34% in children. Weight gain is 
also an important complication of epileptic medications, such as Valproate (2), 
which was introduced to the medicine world in 1970 (3). Fatness is one of the most 
important side effects of this medicine seen in 40% of children and 57% of adults 
(4,5). Therefore, the medication compliance is low, often resulting in increased blood 
pressure, serum levels, diabetes, and coronary artery disease; Increases in weight 
make patients discontinue medication and/or use alternative medicines which may 
again have their own complications/side effects. Literature shows studies that have 
investigated the issue and suggested solutions for the problem (6,7,8). It also needs 
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the weight in the patients of each group, and the Chi-2 test 
for comparison between the two groups. The association 
between “age over 10 years old and high BMI” and 
weight gain was evaluated using Fisher’s exact test. 
Results
Prior to treatment initiation, both groups were similar 
regarding age, sex, BMI before the treatment (P<0.2, 
Table l).
 Following therapy, results of the group receiving 
Phenobarbital showed that 6-7%, 80% and 3% had 
“reduced, no change and increased BMI respectively; 
26 patients who had normal weight before the treatment, 
remained as such after; three, who had normal weight 
previously gained weight after the treatment, and those 
who had been fat prior to treatment remained the fat after 
(P<0.6).
In the Valproate consuming group, 33.3% remained 
without any change and 66.7% gained weight. Ten 
patients who had normal weight before treatment 
remained normal after treatment. Eighteen, who had 
normal weight, prior to treatment gained weight after; 
2, who were fat before treatment, remained fat after 
(P<0.0001). Of patients that gained weight, 2 (10%) 
were previously fat, whereas among those without any 
gain or change, none were previously fat (P<0.4). 
The percentages of weight gain were 66.7 and 13.3% 
in the case & control groups respectively (P<0.0001) 
(Table 2).
Of the Valproate users, among those who gained weight, 
6(30%) were over 10 years old; among patients who 
gained weight, 5 (25%) were female. Of those without 
any weight gain, 3 (80%) were females and one (10%) 
was over 10 years old (P<0.2) and (P<0.2) (Table 3).
to be determined whether the culture and related patterns 
of eating habits play a role and what other factors, if any 
affect the problem. To assess and compare the effects 
of Na Valproate and Phenobarbitol, we investigated 
epileptic children, referring to the Mofid hospital during 
2005, treated with Valproate and Phenbarbitol.
Materials & Methods
In this sequential randomized matched double blind 
trial, 60 epileptic children, aged between 3 to 15 years 
and being treated with Valproate or Phenobarbital 
monotherapy, were investigated. Exclusion criteria were: 
1. Cessation of medication within 2 months of initiation. 
2. Any history of illness constituting a contraindication for 
Valproate usage. 3. Concurrent use of these medications 
leading to weight gain. 4. Gastrostomy tube. 5. Mental 
retardation. Diagnosis was based on ILAE criteria; 
age, sex, and primary BMI were documented. Those 
with a BMI higher than the 95% percentile curve were 
considered ‘fat’(1). 
Patients were randomly assigned into two groups of 
cases, using Valproate, and controls given Phenobarbital; 
Phenobarbital was administered at a dose of 5mg/kg/day 
for 6 months, while valproate was given 20mg/kg/day 
for 6 months. 
Patients were followed for six months, after which BMI 
changes were evaluated and recorded and compared 
to the previous data. Changes between -0.1 to 0.1, less 
than -0.1, and over 0.1 were considered to be ‘without 
change’, ‘reduction’ and ‘increase’ respectively.
The parents were educated on other side effects of 
Valproate, and taught that 2 months is the minimum 
period required to demonstrate any weight change. Data 
were evaluated using the Mc Nemar test for increase in 
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Table 1: Characteristics of study patients.
Medication Age(yr)
Sex BMI Weight
girl boy thin appropriate fat
Phenobarbital (n=30) 8±3.1 14(46.7) 16(53.3) 15.8±1.8 1 28 1
Valproate 
(n=30) 8.±3.2 8(26.7) 22(73.3) 16.4±2.4 2 26 2
Results P<0.8 P<0.2 P<0.4 P<0.4
17Iran J Child Neurology  Feb. 2007
Table 2: Changes in the BMI of patients
          Changes
BMI Reduced Without change Increased Total
Phenobarbital 2 (6.7) 24(80) 4(13.3) 30(100)
Valproate 0(6) 10(33.3) 20(66.7) 30(100)
Table 3: Characteristics of children on Valproate therapy























Our study have demonstrated more weight gain in children using Na Valproate as compared to Phenobarbital (P<0.0001), 
a finding that is in agreement with others (4,9).
Many factors result in weight gain; although it results in an increased appetite, it does not effect the total calorie and 
carbohydrate intake (6). Another factor is damaged termogenesis caused by sympathetic activities dysfunction. Valproate 
usage affects the hypothalamic neurons and reduces the catecholamine response to carbohydrates(7).
The Leptin protein produced by the OB gene in fat cells, increases with fatness or increased weight; other factors,are 
including the reduced level of blood sugar due to the increased insulin level, reduced gluconeogenesis,and fatty acids 
oxidation, and decreased albumin affinity (10).
The direct effect on hunger or appetite center has ruled out and carnitine level has not a great important role (6). 
Regarding limitations of this study, the finding, not statistically significant, that chances of gaining weight following use 
of Valproate, are higher in epileptic children aged over 10 years, could be a consequence of the small sample size of our 
study; this is similar to the findings of the study conducted by Wirrell and colleagues (9).
Novak and associates, in a study conducted on 55 patients, age range 1.8 to 16.9 years, showed weight and BMI increase 
have a direct relation with BMI at initiation of treatment, although are not related to ages, sex, time of treatment start 
and the medication dose (11).
Again in our study, as revealed, the possibility of weight gain is higher in children on Valproate, difference not statistically 
significant; this finding agrees with those of the Novak study (1), although it differs with those of the Dinesen study, 
which revealed no such difference; Dinesen found that only patients with a familial disposition to fatness and diabetes 
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mellitus had higher risks of gaining weight following 
Valproate therapy (5).
In all these studies the reason for the differences in findings 
was the small sample sizes; hence any evaluation of the 
risk factors of weight gain following Valproate therapy, 
needs investigation of larger sample sizes.
According to our results no significant difference in 
weight gain was observed between male and female 
patients; (63% in females and 68% in males), this is in 
accordance with results of previous studies (5-11).
Conclusion
Usage of Valproate in epileptic patients results in weight 
gain, especially in those in their teen years and with 
higher BMIs. More studies with larger sample sizes 
are necessary to determine and clarify the risk factors 
affecting weight gain in epileptic patients.
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